An observational study in Coronary Artery Disease (CAD), sponsored by HeartFlow, Inc.. Recruiting at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by HeartFlow, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Coronary Artery Disease by HeartFlow, Inc. — 4 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · HeartFlow, Inc..
Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 10th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →4 of the 12 studies in Coronary Artery Disease by HeartFlow, Inc. are open now, in 1 country. Recruiting first, the newest first:
HeartFlow, Inc. · Sites in United States
Healthy volunteers
HeartFlow, Inc. · Sites in United States
Ages 40–79
HeartFlow, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 5,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 350 across the 5 interventional studies, 584 across the 7 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
HeartFlow, Inc. is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
2 of the studies in Coronary Artery Disease by HeartFlow, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831409HeartFlow, Inc.Using CTA Measures to Define Cardiac Risk In NFL Alumni | 2026-12-31 |
| NCT07834372HeartFlow, Inc.REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Coronary Artery Disease by HeartFlow, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of Heartflow's NAVIGATE-PCI Registry is to collect observational data about the management of patients before and after deployment of Heartflow's PCI Navigator.
Heartflow's NAVIGATE-PCI Registry is a post-market, multi-center, data collection registry assessing confidence in procedure planning, time of procedure, contrast usage during procedure, radiation usage during procedure, invasive imaging (angiographic or other), and resource utilization. Sites will provide retrospective data from patients receiving an elective PCI prior to the deployment of PCI Navigator vs. after deployment and operator training on how to use the information provided by PCI Navigator. Baseline demographic, medical history, procedural, and in-hospital outcome information will be collected following the procedure. No post discharge follow-up data will be collected.
Deidentified data will be collected for all patients included in the registry who had a CCTA with acceptable image quality prior to elective PCI and are included by the site in the registry. Patients with prior CABG or patients with intervention planned in a previously stented vessel territory are excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (all must be present):
This group includes consecutive patients who have undergone a CCTA a maximum of 90 days prior to an elective PCI at the study site; the CCTA is not required to have been used in procedural planning but must have acceptable image quality according to Heartflow's image quality requirements
This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan after initial invasive angiographic images are reviewed but before reviewing the information provided by the PCI Navigator, and then again after reviewing the information provided by the PCI Navigator. Usage of invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.
Diagnostic Test: Heartflow PCI Navigator
This group includes patients who had a CCTA and a referral for elective PCI following the introduction of the PCI Navigator at the study site. The PCI should be performed no more than 90 days following the CCTA. Interventionalists will document their procedural plan before reviewing the information provided by the PCI Navigator and prior to initial invasive angiographic imaging, and then again after reviewing the information provided by the PCI Navigator. Usage of angiographic and other invasive imaging following review of the PCI Navigator is at the discretion of the interventionalist.
Diagnostic Test: Heartflow PCI Navigator
Heartflow PCI Navigator is the only integrated, AI-driven PCI planning tool that gives interventional cardiologists a patient-specific 3D model, detailing anatomy, plaque composition, and lesion-specific physiology, all aligned to optimize potential stent placement. PCI Navigator delivers a streamlined view of essential information for cath lab decision-making by integrating all relevant measurements, including IVUS-like and FFR-like pullback visualizations, into one seamless experience, which typically requires significant time and effort to obtain in the cath lab.
Primary Endpoint
The primary endpoint will be assessed only in Group 2 and is a change in procedural plan following review of the information provided by PCI Navigator compared to procedural plan with angiographic imaging alone. The primary endpoint will be measured by calculating the percentage of patients in whom a change of plan was documented following review of the PCI Navigator tool compared to the plan documented prior to using the tool.
Time frame: 90 Days
Changes in confidence with and without PCI Navigator (assessed in Groups 2 and 3 as two separate analyses)
Time frame: 90 days for Group 2, 18 months for Group 3
Change in procedural time with and without PCI Navigator
Time frame: 90 days
Change in contrast usage with and without PCI Navigator
Time frame: 90 days
Change in radiation usage during PCI with and without PCI Navigator
Time frame: 90 days
Change in invasive imaging (angiographic or other) with and without PCI Navigator
Time frame: 90 days
Change in resource utilization with and without PCI Navigator
Time frame: 90 days
Exploratory and Safety Endpoint
Perform all endpoint analyses with a comparison of male vs. female as an added variable
Time frame: 5 years
Exploratory and Safety Endpoint
Procedural complications and in-hospital outcomes
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Aug 2026, 5 months.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HeartFlow, Inc.